Trace Neuroscience is a biopharmaceutical company developing genomic therapies for neurodegenerative diseases, with a focus on treating amyotrophic lateral sclerosis (ALS) by restoring the UNC13A protein.

Seaport Therapeutics develops neuropsychiatric medicines using its Glyph technology platform to enhance oral bioavailability and reduce side effects, with a focus on treating depression, anxiety, and other disorders.

Candid Therapeutics, Inc. is a biotechnology company developing transformative therapies for autoimmune diseases.

ARTBIO is a clinical-stage biotech firm specializing in developing alpha radioligand therapies for cancer treatment, currently advancing its proprietary technology and lead prostate cancer program through clinical trials.

Terremoto Biosciences is a biotechnology company that has raised $175 million in a Series B financing round to advance its platform and support the development of multiple in-house programs targeting diseases of high unmet medical need.

Rapport Therapeutics is a clinical-stage biotechnology company that develops precision neuromedicines for seizure and psychiatric disorders by targeting specific neuroanatomical regions, aiming to provide better alternatives to current treatments by reducing unwanted drug-target interactions.